Oftalmol Zh.2009;5:30-34.
http://doi.org/10.31288/oftalmolzh200953034
ERETHROPOIETIN AND SOLUTION CD44 LEVELS IN PATIENTS WITH PRIMARY OPEN-ANGLE GLAUCOMA
Tharwart H. Mokbel,* MD — Asaad A. Ghenem,* MD — Lameaa F. Arafa, ** MD — Azza A. El-Biomy,*** MD.
Departments of Ophthalmology, ** Medical Biochemistry and ***Clinical Pathology, Faculty of Medicine, Mansoura University, Egypt
Abstract:
Purpose: To evaluate the levels of erethropoietin (EPO) and soluble CD44 (sCD44) in the aqueous humor and plasma of patients with primary open-angle glaucoma and the relation to visual fields loss. Patients and methods: Thirty patients with primary open-angle glaucoma (POAG) and twenty five patients with senile cataracts (control group) of matched age and gender were included in the study. Aqueous humor samples were obtained by paracentesis from glaucoma and cataract patients who were undergoing elective surgery. Aqueous humor and corresponding plasma samples were analysed for EPO and sCD44 concentrations by enzyme linked immunosorbent assay. Results: EPO and sCD44 levels revealed a high significant rise in aqueous humor of POAG patients and non-significant rise in plasma of the same patients, in comparison with cataract patients. A high positive correlation between EPO and sCS44 in aqueous humor of POAG patients. In addition, sCD44 concentration was greater in patients with visual field loss. Conclusion: Increased levels of aqueous humor EPO and sCD44 may play an important role in the pathogenesis of POAG. Positive correlation between sCD44 in aqueous of POAG and severity of visual field loss concluding that sCD44 concentration in aqueous humor is a possible protien bio-marker foe visual field deterioration in POAG patients.
Key words: Glaucoma, Erythropoietin, soluble CD44.
References
1.Fan B. J., Wang D. Y., Lam D. S. et. al. Gene mapping for primary open-angle glaucoma // Clin. Biochem. — 2006. — Vol. 39. — P. 249-258.
2.Schwartz M. Lessons for glaucoma from other neurode-generative disease: can one treatment suit them all? // J. Glaucoma. — 2005. — Vol. 14. — P. 321-323.
3.Chen J, and Snith L. H. A double edged sword: Erythro-poietin eyed in retimopathy of prematuity // Journal of AAPOS. — 2008. — Vol. 12. — P. 221-222.
4.Tsai J. C., Song B. J., Liwu B. A. and Forbes M. Erythro-poietin: A candidate neoroprotective agent in the treatment of glaucoma // J. Glaucoma. — 2007. — Vol. 16. — P. 567571.
5.Arjamaa O., Nikinmaa M. Oxygen-dependent diseases in the retina: role of hypoxia-inducible factors // Exp. Eye Res. — 2006. — Vol. 83. — P. 473-483.
6.Choi J., Miller A. M., Nolan M. J. et al. Soluble CD44 in cytotoxic to trabecular meshwork and retinal ganglion cells in vitro // Invest. Ophthalmol. Vis. Sci. — 2005. — Vol. 46. — P. 214-222.
7.Knepper P. A., Miller A. M., Choi J. et al. Hypophos-phorylation of aqueous humor sCD44 and primary open-angle glaucoma // Invest. Ophthalmol. Vis. Sci. — 2005. — Vol. 46. — P. 2829-2837.
8.Asplund T., Heldin P. Hyaluronan receptors are expressed on human malignant mesothelioma cells but not on normal mesothelial cells // Cancer Res. — 1994. — Vol. 54. — P. 4516-4523.
9.Kerrigan L. A., Zack D. J., Quigley H. A. et al. TUNEL-positive ganglion cells in human primary open-angle glau-coma // Arch. Ophthalmol. — 1997. — Vol. 115. — P. 1031-1035.
10.Xenocostas A., Cheung W., Farrell F. et al. The pharmaco-kinetics of erythropoietin in the cerebrospinal fluid after intravenous administration of recombinant human eryth-ropoietin // Eur. J. Clin. Pharmacol. — 2005. — Vol. 61. — P. 189-195.
11.Cumurcu T., Bulut Y., Demir H. D. and Yenisehirli G. Aqueous humor erythropoietin levels in patients with primary open-angle glaucoma // J. Glaucoma. — 2007. — Vol. 16. — P. 645-648.
12.Auricchio A., River V. M., Clackson T. et al. Pharmacological regulation of protein expression from adeno-associated viral vectors in the eye // Mol. Ther. — 2002. — Vol. 6. — P. 238-242.
13.Wenger R. H. Cellular adaptation to hypoxia: O2-sens-ing protein hydroxylases, hypoxia-inducible transcription factors, and O2-regulated gene expression // FASEB. — 2002. — Vol. 16. — P. 1151-1162.
14.Kawakami M., Sekugichi S., Sato K. et al. Erythropoietin receptor mediated inhibition of exocytotic glutamate release confers neuroprotection during chemical ischemia // J. Biol. Chem. — 2001. — Vol. 276. — P. 39469-39475.
15.Tasi J. C., Hwang D. H., Wu L. et al. Retinal function as-sessment following intravitreal injection of erythropoietin in rats: a dose toxicity study // Invest. Ophthalmol. Vis. Sci. — 2006. — Vol. 47: E-abstract 5724.
16.Brines M. and Cerami A. Emerging biological roles for erythropoietin in the nervous system // Nat. Rev. Neurosci. — 2005. — Vol. 6. — P. 484-494.
17.Watanabe D., Suzuna K., Matsui S. et al. Erythropoi-etin as a retinal angiogenic factors in proliferative diabetic retinopathy // N. Eng. J. Med. — 2005. — Vol. 353. — P. 782-792.
18.Tanaka T., Matsumoto M., Inagi R. et al. Induction of protective genes by cobalt ameliorates tubulointerstitial injury in the progressive nephritis // Kidney Int. — 2005. —
Vol. 68. — P. 2714-2725.
19.Nolan M. J., Giovingo M. C., Miller A. M. Aqueous humor sCD44 concentration and visual field loss in primary open-angle glaucoma // J. Glaucoma. — 2007. — Vol. 16. — P. 419-429.
20.Cichy J. and Pure E. The liberation of CD44 // J. Cell. Biol. — 2003. — Vol. 161. — P. 839-843.
21.Miller A. M., Nolan M. J., Choi J. et al. Lactate treatment causes NK-kB activation and CD44 shedding in cultured trabecular meshwork cells // Invest. Ophthalmol. Vis. Sci. — 2007. — Vol. 48. — P. 1615-1621.
22. Murphy J. F., Lennon F., Steele C. et al. Engagement of CD44 modulates cyclooxygenase induction, VEGF generation, and proliferation in human vascular endothelial cells // FASEB. — 2005. — Vol. 19. — P. 446-448.
23. Knepper P. A., Mayanil C. S. K., Goossens W. et al. Aqueous humor in primary open-angle glaucoma contains an increased level of CD44 // Invest. Ophthalmol. Vis. Sci. — 2002. — Vol. 43. — P. 133-139.